Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06770049 · ClinicalTrials.gov registry record · Phase 4
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
A Phase 4 study of Obesity, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 228
- Enrollment target
- 1
- Study location
NCT06770049: Recruiting Phase 4 study of Obesity, sponsored by Mayo Clinic.
NCT06770049 is a Phase 4 study of Obesity that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 228 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06770049, a Phase 4 study of Obesity, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 228 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop an evidence-based precision medicine approach for obesity that enhances weight loss and promotes weight loss maintenance.
Primary Outcome
Change in Total Body Weight Loss (TBWL) in kg
Conditions Studied
Interventions
- BEHAVIORAL Standard Lifestyle Intervention (SLI) program
- BEHAVIORAL Phenotype-tailored Lifestyle Intervention (PLI) program
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2030-12 |
| Phase | Phase 4 |
What NCT06770049 shows while recruiting
NCT06770049 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Standard Lifestyle Intervention (SLI) program is the first listed.
NCT06770049 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06770049 about?
NCT06770049 is a clinical study titled "Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial". The purpose of this study is to develop an evidence-based precision medicine approach for obesity that enhances weight loss and promotes weight loss maintenance.
What is the current status of trial NCT06770049?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 228 participants. The study started on 2025-01-22. Estimated completion is 2030-12.
What conditions does trial NCT06770049 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06770049?
The interventions under investigation include: Standard Lifestyle Intervention (SLI) program (BEHAVIORAL), Phenotype-tailored Lifestyle Intervention (PLI) program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06770049?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06770049 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06770049's enrollment target sits among peer trials
228 283rd of 1053 higher than 770 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
-
A Study of a Novel Precision Medicine Approach For Obesity
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI